Filing Analysis
TherapeuticsMD, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2026. The filing serves as a formal announcement of the press release containing these results.
📋 Key Facts
- The company announced financial results for the quarter ended June 30, 2026.
- The announcement was made via a press release dated August 11, 2026.
- The filing incorporates Exhibit 99.1 as the primary source of financial information.
TherapeuticsMD, Inc. announced its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished as an exhibit to the filing under Regulation FD.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026.
- Press release issued on May 12, 2026.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
- Marlan Walker is the current Chief Executive Officer.
TherapeuticsMD, Inc. announced its full-year 2025 financial results on March 30, 2026. The disclosure was made via a press release furnished as Exhibit 99.1 and incorporated by reference into Items 2.02 and 7.01.
📋 Key Facts
- Report date and earliest event date: March 30, 2026.
- Announcement covers the full fiscal year ended December 31, 2025.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
- Press release is furnished as Exhibit 99.1.
- Marlan Walker, CEO, signed the report.
TherapeuticsMD, Inc. has appointed Carr, Riggs & Ingram, L.L.C. (CRI) as its new independent registered public accounting firm, replacing Berkowitz Pollack Brant Advisors + CPAs (BPB). The change follows a transaction where CRI acquired BPB's capital markets practice assets.
🚩 Red Flags
- Going concern language: The filing confirms that previous audit reports (FY 2023 and FY 2024) included an explanatory paragraph describing uncertainty about the company's ability to continue as a going concern.
- Auditor change combined with existing going concern issues increases risk profile.
📋 Key Facts
- Effective date of auditor change: January 15, 2026.
- New Auditor: Carr, Riggs & Ingram, L.L.C. (CRI).
- Outgoing Auditor: Berkowitz Pollack Brant Advisors + CPAs (BPB).
- The company stated there were no disagreements with BPB regarding accounting principles or auditing procedures.
- Previous audit reports for fiscal years 2023 and 2024 included an explanatory paragraph regarding the uncertainty of the Company's ability to continue as a going concern.
TherapeuticsMD, Inc. held its 2025 Annual Meeting of stockholders on December 15, 2025. The meeting resulted in the election of four directors and approval of several key shareholder proposals, including an increase in authorized shares.
🚩 Red Flags
- Significant increase in authorized shares (to 640M) can potentially lead to future dilution if used for equity financing.
📋 Key Facts
- Annual Meeting held on December 15, 2025.
- Quorum was established with 6,842,247 shares represented (out of 11,574,362 outstanding).
- All four nominees for the Board of Directors were elected: Tommy G. Thompson, Cooper C. Collins, Gail K. Naughton, Ph.D., and Justin Roberts.
- Stockholders approved a non-binding advisory vote on executive compensation (Say-on-Pay) for FY2024.
- Stockholders approved a 1-year voting frequency for future Say-on-Pay votes.
- Ratified the appointment of Berkowitz Pollack Brant Advisors + CPAs, LLP as independent auditors for FY2025.
- Approved an amendment to increase authorized common stock to 640,000,000 shares.
TherapeuticsMD, Inc. filed an 8-K to announce its third quarter 2025 financial results for the period ended September 30, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly financial results (Item 2.02).
- Reporting date: November 12, 2025.
- Financial results pertain to the quarter ended September 30, 2025.
TherapeuticsMD, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2025. The filing serves as a formal announcement of the earnings press release issued on August 12, 2025.
📋 Key Facts
- Report date: August 12, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing incorporates a press release (Exhibit 99.1) regarding Q2 2025 financial results.
- The company is listed on the Nasdaq Stock Market under ticker TXMD.
TherapeuticsMD, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025. The filing serves as a formal announcement of the earnings press release issued on May 13, 2025.
📋 Key Facts
- The company announced Q1 2025 financial results (quarter ended March 31, 2025).
- Filing date: May 13, 2025.
- The report includes a press release as Exhibit 99.1.
TherapeuticsMD, Inc. has filed a lawsuit against Mayne Pharma LLC in the U.S. District Court for the District of Delaware. The litigation seeks damages for breach of contract and fraudulent inducement related to existing disputes over net working capital allowances under their 2022 License and Transaction Agreements.
🚩 Red Flags
- Litigation risk: Legal battles can lead to significant legal expenses and uncertainty regarding the outcome of contractual disputes.
📋 Key Facts
- Lawsuit filed on April 8, 2025, in the U.S. District Court for the District of Delaware.
- Defendant: Mayne Pharma LLC.
- Claims include breach of contract, breach of implied covenant of good faith and fair dealing, fraudulent inducement, and unjust enrichment.
- Dispute stems from previously disclosed issues regarding net working capital allowances under agreements dated December 4, 2022.
TherapeuticsMD, Inc. filed an 8-K to announce its full year 2024 financial results via a press release. The filing serves as a formal mechanism to furnish the earnings announcement under Item 7.01 and Item 2.02.
📋 Key Facts
- The company announced full year 2024 financial results on March 27, 2025.
- Financial results are contained in Exhibit 99.1 (Press Release).
- The filing is made pursuant to Items 2.02 and 7.01 of Form 8-K.
TherapeuticsMD, Inc. held its 2024 Annual Meeting of stockholders on December 5, 2024. The meeting resulted in the election of four directors and the ratification of the company's independent auditor.
📋 Key Facts
- Annual Meeting held on December 5, 2024.
- Quorum was established by holders of 6,832,199 shares (representing approx. 59% of outstanding common stock).
- Four directors elected: Tommy G. Thompson, Cooper C. Collins, Gail K. Naughton, Ph.D., and Justin Roberts.
- Non-binding advisory vote on executive compensation for FY2023 was approved.
- Ratified Berkowitz Pollack Brant Advisors + CPAs, LLP as independent auditor for FY2024.
TherapeuticsMD, Inc. filed an 8-K to announce its financial results for the third quarter ended September 30, 2024. The filing serves as a formal notice that a press release containing these results was issued on November 12, 2024.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2024.
- Filing date: November 12, 2024.
- The company released its Q3 2024 financial results via press release (Exhibit 99.1).
- The filing is made pursuant to Items 2.02 and 7.01.
TherapeuticsMD, Inc. has announced the date for its 2024 Annual Meeting of Stockholders and provided revised deadlines for stockholder proposals and director nominations.
📋 Key Facts
- The 2024 Annual Meeting of Stockholders is scheduled for Thursday, December 5, 2024.
- Record date for voting eligibility is the close of business on October 17, 2024.
- Deadline for Rule 14a-8 stockholder proposals: September 30, 2024.
- Deadline for director nominations or other proposals: Close of business on September 30, 2024.
TherapeuticsMD, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Q2 2024).
- Report date: August 12, 2024.
- Financial results are provided via an attached press release (Exhibit 99.1).
TherapeuticsMD, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing serves as a formal notice that a press release containing these results has been issued.
📋 Key Facts
- The company announced its Q1 2024 financial results on May 10, 2024.
- Financial results cover the period ending March 31, 2024.
- The filing incorporates a press release as Exhibit 99.1.
TherapeuticsMD, Inc. filed an 8-K to announce its full year 2023 financial results via a press release. The filing serves as a formal mechanism to furnish the earnings announcement under Regulation FD.
📋 Key Facts
- The company announced its full year financial results for the period ended December 31, 2023.
- The announcement was made on March 29, 2024.
- Financial results were released via a press release (Exhibit 99.1).